Head-to-head evidence
Inbrija (CVT-301) vs TR-012001
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
Inbrija (CVT-301)
Marketed by Merz Therapeutics
NCT02240030 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 351 participants and a clinical primary endpoint based on the UPDRS Part III motor score. Although the primary score numerically favored high-dose CVT-301 over placebo, the registry does not state whether that primary comparison was statistically significant, so the result remains unclear.
TR-012001
Developed by SNLD, Ltd.
NCT06212089 · Phase 2 · completed
The study randomly assigned 12 participants to TR-012001 or placebo and masked participants, but it was single-blind and very small. Because no results are posted, it cannot establish whether the primary safety comparisons were favorable or statistically significant.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Inbrija (CVT-301)'s landscape · TR-012001's landscape